NEW YORK, February 1, 2017 /PRNewswire/ --
The Biotech industry remains under intense pressure due to political andmedia focus on high drug prices, as well as the changing competitive scenario weighing on the sector. However, its fundamentals remain strong, with M&A, product approvals, and positive data flow to act as catalysts, according to a Zacks' report.
On Tuesday, shares in New York headquartered Intercept Pharmaceuticals Inc. recorded a trading volume of 408,238 shares. The stock ended the session 3.74% higher at $109.75. The Company's shares have gained 0.44% in the last one month and 1.01% since the start of this year. The stock is trading 1.76% above its 50-day moving average. Moreover, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have a Relative Strength Index (RSI) of 53.16.
On December 14th, 2016, Intercept Pharmaceuticals announced that the European Commission has granted conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
On January 20th, 2017, research firm Needham downgraded the Company's stock rating from 'Buy' to 'Hold'. Your complete research report on ICPT can be retrieved for free at:
Summerville, South Carolina headquartered Aeterna Zentaris Inc.'s stock closed the day 21.15% higher at $3.15. A total volume of 3.06 million shares was traded, which was above their three months average volume of 279,030 shares. The Company's shares are trading 4.52% below their 50-day moving average. Additionally, shares of Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, have an RSI of 56.68.
On January 17th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $7 a share to $10 a share.
On January 30th, 2017, Aeterna Zentaris announced the occurrence of the 384th death in the pivotal Phase-3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with Zoptrex™ (zoptarelin doxorubicin) in women with advanced, recurrent or metastatic endometrial cancer, representing the clinical endpoint of the study. The Company currently expects to lock the clinical database and to report top-line results in April 2017. A free report on AEZS is just a click away at:
Shares in Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc. recorded a trading volume of 530,959 shares, which was above their three months average volume of 473,650 shares. The stock ended yesterday's trading session 7.85% higher at $63.06. The Company's shares have advanced 24.67% in the past month, 33.07% over the previous three months, and 26.37% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.65% and 19.40%, respectively. Furthermore, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 63.23.
On January 09th, 2017, Spark announced new four-year data from a Phase-1 clinical trial and natural history study findings that enhance the understanding of investigational voretigene neparvovec, a one-time adeno-associated viral gene therapy for Inherited Retinal Disease caused by biallelic RPE65 mutations. The Company also announced that the US FDA has granted a request to amend the orphan drug designation for voretigene neparvovec to "the treatment of inherited retinal dystrophy due to biallelic RPE65 mutations". Sign up for your complimentary research report on ONCE at:
Leawood, Kansas headquartered Aratana Therapeutics Inc.'s stock finished Tuesday's session 5.55% higher at $7.99 with a total trading volume of 351,464 shares. The Company's shares have advanced 11.28%, both, in the last one month and since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.63% and 4.05%, respectively. Additionally, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide, have an RSI of 56.39.
On January 24th, 2017, Elanco Animal Health, a division of Eli Lilly and Co., and Aratana announced a new targeted tool for the management of pain and inflammation associated with canine osteoarthritis. Galliprant®, a first-in-class piprant, is now available to veterinarians for once-daily use in dogs with OA. Galliprant can be used in patients as young as 9 months, weighing 8 pounds or more. Register for free on Stock-Callers.com and download the latest research report on PETX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!